Table 5.
Factors associated with overall survival in univariate and multivariate analyses.
| Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| Gender | ||||||
| Male vs. Female | 0.90 | 0.61–1.34 | 0.612 | |||
| Age | ||||||
| 65–75 vs. >75 | 0.79 | 0.53–1.16 | 0.224 | |||
| EOCG performance status | ||||||
| 0–1 vs. 2 | 0.46 | 0.33–0.72 | <0.001 | 0.54 | 0.34–0.85 | 0.007 |
| Histology | ||||||
| Adenocarcinoma vs. Nonadenocarcinoma | 0.88 | 0.52–1.48 | 0.620 | |||
| EGFR mutation | ||||||
| Exon 19 deletion vs. Exon 21 L858R | 0.99 | 0.68–1.46 | 0.999 | |||
| Smoking status | ||||||
| Present or former smoker vs. Nonsmoker | 1.38 | 0.93–2.02 | 0.115 | |||
| Smoking Index | ||||||
| ≥600 vs.<600 | 1.06 | 0.72–1.55 | 0.777 | |||
| Second-line treatment | ||||||
| Yes vs. No | 0.67 | 0.45–0.99 | 0.045 | 0.95 | 0.63–1.46 | 0.833 |
| Comorbidity | ||||||
| Yes vs. No | 1.23 | 0.83–1.82 | 0.300 | |||
| T stage | ||||||
| T1–2 vs. T3–4 | 0.60 | 0.41–0.87 | 0.008 | 0.56 | 0.37–0.85 | 0.007 |
| N stage | ||||||
| N0–1 vs. N2–3 | 0.80 | 0.54–1.18 | 0.258 | |||
| CNS metastases | ||||||
| Yes vs. No | 1.20 | 0.82–1.76 | 0.342 | |||
| No. of metastases | ||||||
| 1–2 vs. 3–5 | 0.62 | 0.42–0.92 | 0.016 | 0.86 | 0.57–1.29 | 0.458 |
| LCRT for both PT and OS | ||||||
| Yes vs. No | 0.48 | 0.32–0.72 | <0.001 | 0.41 | 0.27–0.63 | <0.001 |
NSCLC, non-small cell lung cancer; Smoking Index, number of cigarettes smoked per day × years of smoking; ECOG PS, Eastern Cooperative Oncology Group Performance Status; CNS, Central Nervous System; EGFR, Epidermal Growth Factor Receptor; PT, Primary Tumor; OS, Oligometastatic Sites; LCRT, Local Consolidative Radiation Therapy.
The bold values indicate significant P values.